Cargando…

Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study

BACKGROUND: On September 5, 2019, British Columbia announced a new policy (the Biosimilars Initiative) to switch from originator to biosimilar infliximab for patients with inflammatory bowel diseases. OBJECTIVE: To monitor the impacts of the policy on the use of medications and health services durin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fisher, Anat, Kim, Jason D., Dormuth, Colin R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995207/ https://www.ncbi.nlm.nih.gov/pubmed/36911254 http://dx.doi.org/10.1155/2023/2794220

Ejemplares similares

Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study
por: Fisher, Anat, et al.
Publicado: (2022)

Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia
por: Fisher, Anat, et al.
Publicado: (2022)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta
por: Kaplan, Gilaad G, et al.
Publicado: (2020)

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2018)

Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
por: Martínez-Feito, Ana, et al.
Publicado: (2020)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
por: Huoponen, Saara, et al.
Publicado: (2020)

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
por: Massimi, Davide, et al.
Publicado: (2021)

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
por: Fischer, Sarah, et al.
Publicado: (2021)

Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices
por: Bhat, Shubha, et al.
Publicado: (2021)

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
por: Fleischmann, Roy, et al.
Publicado: (2020)

Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2018)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report
por: Strik, Anne S., et al.
Publicado: (2019)

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar
por: Meijboom, Rosanne W., et al.
Publicado: (2023)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
por: Nakagawa, Tomoo, et al.
Publicado: (2019)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial
por: Goll, G. L., et al.
Publicado: (2019)

Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review
por: Bashir, Naazish S., et al.
Publicado: (2023)

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
por: Petit, Juliette, et al.
Publicado: (2021)

Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan
por: Sagami, Shintaro, et al.
Publicado: (2021)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
por: Pierik, Marieke J, et al.
Publicado: (2021)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
por: Derikx, Lauranne A A P, et al.
Publicado: (2021)

Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study
por: Mazza, Stefano, et al.
Publicado: (2021)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
por: Peng, Kuan, et al.
Publicado: (2023)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Chronic Inflammatory Demyelinating Polyneuropathy After Therapy With Infliximab Biosimilar
por: Larson, Jessica, et al.
Publicado: (2023)

In the Wake of a Pandemic: Revisiting School Approaches to Nonmedical Exemptions to Mandatory Vaccination in the US
por: Paquette, Erin Talati
Publicado: (2021)

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
por: Abdalla, Abuelmagd, et al.
Publicado: (2017)

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease
por: Kashima, Shin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nd8q9m40hj2ham7fs9udrrup5t